Clinical Trials on Chronic Lymphoproliferative Diseases

Total 377797 results

iOMEDICO AG
AstraZeneca

Recruiting

Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO) (CICERO)

CLL

Germany
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
Acerta Pharma BV

Active, not recruiting

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Chronic Lymphocytic Leukemia

United States, United Kingdom, Belgium, Spain, Israel, France
Canadian Cancer Trials Group

Active, not recruiting

Economic Analysis of Alliance A041202 CLL Study

Chronic Lymphocytic Leukemia

Canada
Juno Therapeutics, Inc., a Bristol-Myers Squibb...
Celgene Corporation

Withdrawn

A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Leukemia, Lymphocytic, Chronic, B-Cell

United States, Austria, Belgium, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom
German CLL Study Group

Active, not recruiting

Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL (CLL2-BZAG)

Chronic Lymphoid Leukemia

Germany
German CLL Study Group

Active, not recruiting

Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL (CLL-Frail)

Chronic Lymphoid Leukemia

Austria, Germany
Mayo Clinic

Recruiting

The Effects of Acute and Chronic Exercise on Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients

Indolent Non-hodgkin Lymphoma | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Pirtobrutinib and Venetoclax Combined With Minimal Residual Disease Detection for Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Ohio State University Comprehensive Cancer Center

Active, not recruiting

Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

Chronic Lymphocytic Leukemia | Ibrutinib Resistance

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto
Fondazione Adecco per le Pari Opportunità

Completed

Occupational Status and Hematological Disease (EMATO0113)

Hodgkin Disease | Chronic Lymphocytic Leukemia | Chronic Myeloid Leukemia | Chronic Thrombocytopenia | Myelodysplastic Syndrome

Italy
Memorial Sloan Kettering Cancer Center
Adaptive Biotechnologies

Recruiting

Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
Christine Ryan
Genentech, Inc.

Recruiting

A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation

Chronic Lymphocytic Leukemia | Richter's Transformation

United States
University of Wisconsin, Madison
Genentech, Inc.; Celgene Corporation

Withdrawn

Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)
Massachusetts General Hospital
Dana-Farber Cancer Institute

Completed

Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | B Chronic Lymphocytic Leukemia

United States
Celgene Corporation

Completed

Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Leukemia Lymphocytic Chronic B-Cell

United States, Germany
Pharmacyclics LLC.

Completed

Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)

B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Georg Aue, M.D.
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma

United States
M.D. Anderson Cancer Center
Sanofi

Completed

Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias

Leukemia | Richter's Transformation

United States
Wolfson Medical Center

Unknown

Combined Treatment With Fresh Frozen Plasma and Rituximab (Mabthera) in Patients With Advanced Refractory Chronic Lymphocytic Leukemia

Advanced Refractory Chronic Lymphocytic Leukemia

Israel
Vilnius University

Completed

High-dose Methylprednisolone and Rituximab in High Risk B-CLL (LT-CLL-001)

Chronic B-Lymphocytic Leukemia

Lithuania
Oslo University Hospital
University of Oslo; Norwegian University of Science and Technology; University... and other collaborators

Active, not recruiting

A Complex Intervention for Chronically Fatigued Lymphoma Survivors

Chronic Fatigue Syndrome

Norway
Wang Xin

Recruiting

Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma

CLL/SLL

China
Seema Bhat

Recruiting

Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
M.D. Anderson Cancer Center

Active, not recruiting

Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Leukemia (SLL)

United States
M.D. Anderson Cancer Center

Active, not recruiting

Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia

Recurrent Chronic Lymphocytic Leukemia

United States
Pharmacyclics LLC.

Completed

Safety of PCI-32765 in Chronic Lymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells (CLIPA)

Leukemia | Leukemia, B-Cell, Chronic

United States
Advancell - Advanced In Vitro Cell Technologies...
Nexus Oncology Ltd

Completed

Safety and Tolerability Open Label Dose Escalation Study of Acadesine in B-CLL Patients

Leukemia, B-Cell, Chronic

Spain, France, Belgium
Gruppo Italiano Malattie EMatologiche dell'Adulto

Not yet recruiting

Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease Progression

Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center

Active, not recruiting

Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Richter Syndrome | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Weill Medical College of Cornell University
TG Therapeutics, Inc.

Terminated

Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

Chronic Lymphocytic Leukemia | CLL/SLL | CLL Progression

United States
University of California, San Diego

Active, not recruiting

Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

United States
University of Rochester

Active, not recruiting

Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
Memorial Sloan Kettering Cancer Center
Juno Therapeutics, Inc.

Active, not recruiting

A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies

Chronic Lymphocytic Leukemia (CLL) | Refractory | Relapsed

United States
Janssen Research & Development, LLC
Pharmacyclics LLC.

Recruiting

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia (TAILOR)

Leukemia, Lymphocytic, Chronic, B-Cell | Small Lymphocytic Lymphoma

United States, Spain
Merck Sharp & Dohme LLC

Recruiting

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

Chronic Lymphocytic Leukemia | Small Lymphocytic Leukemia

Poland, Turkey, Denmark, Singapore, Hungary, Hong Kong, Chile, Malaysia, Brazil, Guatemala, China, Taiwan, South Africa, Colombia, United States, Ukraine, Australia, Mexico
Dana-Farber Cancer Institute
GlaxoSmithKline; Gilead Sciences

Active, not recruiting

A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Active, not recruiting

Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia (VeRitAs)

Chronic Myeloid Leukemia

Italy
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies

Relapsed/Refractory Chronic Lymphocytic Leukemia

China
AstraZeneca

Recruiting

Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma)

Japan
Dana-Farber Cancer Institute
Secura Bio, Inc.

Recruiting

Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

Chronic Lymphocytic Leukemia | Richter Syndrome

United States
University of Tennessee
AstraZeneca; Vanderbilt University Medical Center

Recruiting

Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence

Multiple Myeloma | Chronic Lymphocytic Leukemia | Chronic Myeloid Leukemia | Multiple Chronic Conditions

United States
Genentech, Inc.

Active, not recruiting

A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Lymphocytic Leukemia, Chronic | Lymphoma, Non Hodgkin

United States, Korea, Republic of, Australia, United Kingdom, Germany, Canada, Spain
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
French Innovative Leukemia Organisation

Recruiting

Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A

Chronic Lymphoid Leukemia

France

Clinical Trials on Chronic Lymphoproliferative Diseases

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations